EUVIMED · CrossrefJournal
Medicinal Chemistry Research
ISSN 1054-2523 · Springer Science and Business Media LLC
Latest articles
Design, synthesis, and biological evaluation of novel p-tert-Butylcalix[4]arene derivatives bearing maleimide units as potential anticancer agents
Lirafugratinib (Lyrfigtu®): a first-in-class, highly selective FGFR2 inhibitor approved for advanced cholangiocarcinoma
New diterpenoids from Croton L. species (2019–2025): structural diversity and bioactivity
Mushroom-derived metabolites: a promising source of novel lead compounds for pharmaceutical and functional food applications
Brepocitinib (Lisraya®), a first orally administered small molecule dual TYK2/JAK1 inhibitor approved for dermatomyositis in adults
Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer
Remibrutinib (Rhapsido®), a covalent Bruton’s tyrosine kinase inhibitor approved for chronic spontaneous urticaria
Zidebactam as a new approved β-Lactamase inhibitor with intrinsic antibacterial activity via PBP2 binding
Unveiling the therapeutic potential of Calotropis procera: from traditional applications to phytochemistry, pharmacology, and safety
O-methylation of phenolic natural products: translational insights from resveratrol
Peptide-based allosteric modulators of AMPA receptors: design, docking and ligand-receptor interactions
Artificial intelligence–assisted lead optimization in drug discovery: bridging computational advances and translational challenges
Effect of pipernonaline from Piper retrofractum on memory disorder in mice and neurite outgrowth activity of PC12 cells
Probing novel azole–sulfonamide urea/thiourea conjugates as multitarget inhibitors of AChE and hCAs (I and II): synthesis, in vitro, and in silico studies
Baxdrostat (Baxfendy®), a first-in-class aldosterone synthase inhibitor approved for adults with uncontrolled hypertension
Repurposing antifolates as G9a methyltransferase inhibitors for potential Alzheimer’s disease therapeutics via 3D QSAR/pharmacophore mapping and experimental validations
Vepdegestrant: the first FDA-approved oral PROTAC and a milestone in targeted protein degradation
Design and biological evaluation of sulfonamide–chalcone hybrids with in vitro tumor-selective cytotoxicity against oral squamous cell carcinoma: SAR, QSAR, and in silico ADME studies
Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications
Optimization of a bis-imine scaffold as a glyoxalase I inhibitor: synthesis, SAR, and docking studies
Investigation of reported small molecule P2Y6 receptor antagonists
Special issue of Medicinal Chemistry Research in honor of Dr. Kenneth A. Jacobson
Review of promising benzimidazole-based anticancer agents (2023-2026)
Alisols A-C and their acetate derivatives: a review of natural occurrence, pharmacology, semisynthesis, pharmacokinetics, and metabolism
In vitro enzymatic assays invalidate dihydromyricetin as a potential inhibitor against enterovirus A71 3C protease: beware of fluorescence quenching artifacts
QSAR modeling and in vitro studies of the selective action of triphenylphosphonium salts as anticancer agents against the rhabdomyosarcoma cell line
Isolation, modification, structure-activity relationship (SAR) and molecular docking studies of isoflavones from Derris scandens as potent dual AChE/BuChE inhibitors
Design and synthesis of pyrrolo[2,3-d]pyrimidine linked diazospiro and piperazine – piperidine libraries as anticancer agents
7-azaindole as privileged scaffold: Advances in drug design and structural modification
Taming the reactive intermediates: the nazarov cyclization as a programmable platform
EUVIMED